Navigation Links
Genedata Phylosopher Selected for ERA-NET sncRNA Project

Genedata Phylosopher® is Central Management Solution for European Consortium Using Systems Biology to Study Infectious Diseases

(PRWEB) June 1, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it has been selected to participate in an ERA-Net-funded applied pathogenomics project, which is using systems biology to identify the role of small non-coding RNA (sncRNA) in infectious diseases. The sncRNAomics European Research Consortium is identifying novel targets for diagnostics and therapy of five major high-risk gram-positive human microbial pathogens. The Genedata Phylosopher biological data management solution was chosen as the central management and infrastructure platform for sharing and interpreting the experimental data, in particular the next-generation sequencing and tiling array data generated within the consortium.

“We chose to partner with Genedata because they have a successful track record in transcriptome-based biomarker identification and also because they have the strongest product portfolio for centralized data management for target validation,” explained Dr. Torsten Hain of the University of Giessen (Germany) and sncRNAomics Project Coordinator. “In health care, and especially in a clinical environment, microbial resistance increases exponentially. Antibiotics have become a blunt sword and we need new approaches in diagnostics and therapy,” continued Dr. Hain. “Small non-coding RNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity is largely unknown. Within this interdisciplinary project we are applying for the first time a systems biology approach on major human pathogens to elucidate the role of sncRNAs, and to identify and validate new sncRNA-based diagnostic biomarkers and drug targets.”

Genedata Phylosopher will integrate all experimental data from the pathogens and the host organisms. Using a genome-wide scale and regulatory network approach, the consortium will adapt high-throughput technologies such as transcriptomics by tiling arrays as well as next-generation sequencing technologies to identify novel sncRNAs and to investigate their role in regulation. Genedata Phylosopher supports the reconstruction of disease pathways, in particular the refinement of functional assignment of genes, transcripts, proteins, regulatory motifs, RNAs and their molecular interactions, to regulatory networks during host-pathogen interactions.

"We are delighted to have this international and interdisciplinary consortium choose Genedata as their central data management and analysis infrastructure,” said Dr. Othmar Pfannes, CEO of Genedata. “This partnership further demonstrates Genedata’s leadership in delivering scalable and flexible research IT infrastructure solutions for target validation, drug development, and biomarker discovery, even for novel target classes such as sncRNAs.”

About sncRNAomics European Research Consortium
Novel anti-infectives are of high priority for global health care and sncRNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity in largely unknown. The consortium brings together seven research groups from three countries to combine novel high-throughput sncRNA screening methods, whole-genome transcriptomics and proteomics and bioinformatics. These methods will be coupled with molecular characterization to provide new data regarding sncRNAs in major high-risk Grampositive microbes (e.g. Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Listeria). Potential new drugs and diagnostic biomarkers will be validated using tissue culture and subsequently in in-vivo models. The sncRNAomics project is granted under the frame of the second multinational ERA-Net PathoGenoMics call. For more information, please visit

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US.


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Expressionist 6 with New Refiner MS Capabilities Debuts at 58th ASMS Conference on Mass Spectrometry
2. German MedSys Project Adopts Genedata Phylosopher for Research Informatics
3. Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference
4. Genedata Announces Five-Year Agreement Extension with Kluyver Centre for Genomics of Industrial Fermentation
5. Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting
6. Evonik Extends Long-term Research & Development Partnership with Genedata
7. RIKEN Center for Genomics Medicine Chooses Genedata Expressionist for High Throughput Proteomics R&D
8. Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies
9. MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
10. Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project
11. Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT
Post Your Comments:
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... (AMA) and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with ... and other AMA team leaders met with OPBAP leaders Capt. Karl Minter and ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... sale of broadly enabling, pressure cycling technology ("PCT")-based sample ... announced it has received gross proceeds of $745,000 from ... (the "Offering"), increasing the total amount raised to date ... closings are expected in the near future. ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):